QCIL Stock Overview
A pharmaceutical manufacturing company, produces treatments for HIV/AIDS, Malaria, Hepatitis, and other products in Uganda. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Quality Chemical Industries Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | USh56.00 |
52 Week High | USh57.00 |
52 Week Low | USh52.00 |
Beta | -0.22 |
11 Month Change | 1.82% |
3 Month Change | 0% |
1 Year Change | 6.67% |
33 Year Change | -41.05% |
5 Year Change | -55.91% |
Change since IPO | -78.63% |
Recent News & Updates
Recent updates
Shareholder Returns
QCIL | UG Pharmaceuticals | UG Market | |
---|---|---|---|
7D | 1.8% | -1.0% | 0.2% |
1Y | 6.7% | 0.8% | 4.2% |
Return vs Industry: QCIL exceeded the UG Pharmaceuticals industry which returned 0.8% over the past year.
Return vs Market: QCIL exceeded the UG Market which returned 4.2% over the past year.
Price Volatility
QCIL volatility | |
---|---|
QCIL Average Weekly Movement | 0.7% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 2.4% |
10% most volatile stocks in UG Market | 2.9% |
10% least volatile stocks in UG Market | 1.0% |
Stable Share Price: QCIL has not had significant price volatility in the past 3 months compared to the UG market.
Volatility Over Time: QCIL's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 362 | Ajay Pal | www.qcil.com |
Quality Chemical Industries Limited, a pharmaceutical manufacturing company, produces treatments for HIV/AIDS, Malaria, Hepatitis, and other products in Uganda. It offers antibacterials, anti-hypertensives, vasodilators, anti-emetics, antibiotics, and antidiabetics products; and Lamivudine/Tenofovir Disoproxil Fumarate, Dolutegravir, Efavirenz, and Zidovudine tablets for the treatment of HIV infection. The company also offers Lumartem/Lumet tablets for the treatment of malaria; Texavir and Zentair for the treatment of Hepatitis B; and Isoniazid/Pyridoxine Hydrochloride /Sulfamethoxazole Trimethoprim tablets for the treatment of tuberculosis.
Quality Chemical Industries Limited Fundamentals Summary
QCIL fundamental statistics | |
---|---|
Market cap | USh204.51b |
Earnings (TTM) | USh50.25b |
Revenue (TTM) | USh296.39b |
4.1x
P/E Ratio0.7x
P/S RatioIs QCIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QCIL income statement (TTM) | |
---|---|
Revenue | USh296.39b |
Cost of Revenue | USh161.01b |
Gross Profit | USh135.38b |
Other Expenses | USh85.12b |
Earnings | USh50.25b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 13.76 |
Gross Margin | 45.68% |
Net Profit Margin | 16.96% |
Debt/Equity Ratio | 0% |
How did QCIL perform over the long term?
See historical performance and comparisonDividends
13.6%
Current Dividend Yield67%
Payout RatioDoes QCIL pay a reliable dividends?
See QCIL dividend history and benchmarksQuality Chemical Industries dividend dates | |
---|---|
Ex Dividend Date | Nov 27 2024 |
Dividend Pay Date | Dec 12 2024 |
Days until Ex dividend | 5 days |
Days until Dividend pay date | 20 days |
Does QCIL pay a reliable dividends?
See QCIL dividend history and benchmarks